IONIS PHARMACEUTICALS INC 8K

Ionis Pharmaceuticals reported that its Phase 3 CARDIO-TTRansform trial of eplontersen in ATTR-CM patients did not meet the primary cardiovascular endpoint, though a monotherapy subgroup showed nominal benefit and safety remained favorable.

On July 9, 2026, Ionis Pharmaceuticals, Inc. announced that the CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), conducted with partner AstraZeneca, failed to meet its primary efficacy endpoint of reducing the composite outcome of cardiovascular mortality and recurrent cardiovascular events through Week 140 versus placebo when added to contemporary standard-of-care, which for most patients included TTR stabilizers. A prespecified subgroup analysis showed a nominally significant benefit (hazard ratio 0.71) for patients receiving eplontersen monotherapy compared to placebo, while no treatment effect was seen in patients on stabilizer therapy at baseline. Despite the missed primary endpoint, multiple secondary, imaging, and biomarker measures favored eplontersen, and the drug demonstrated large, sustained reductions in transthyretin and a favorable safety profile consistent with prior results. Ionis emphasized its broader pipeline, ongoing product launches, and reiterated its goal of achieving cash flow breakeven by 2028, while indicating that full trial results will be further analyzed and presented at the European Society of Cardiology Congress in August 2026.

Filing Facts

CIK

874015

Ticker

IONS

Form

8K

Source Type

fda

Accession

0001140361-26-028092

Alert Tier

7